The New Standard of Care: Leveraging the Benefits of SGLT2 Inhibitors Across the Heart Failure Spectrum

Hear from Javed Butler, MD, and Lee Goldberg, MD, as they discuss the importance of integrating SGLT2 inhibitors across the spectrum of heart failure. Improve your ability to initiate SGLT2 inhibitors, download slides to use as a resource, and review expert commentaries on adverse event management and medication adjustment considerations.

Share

Program Content

Activities

SGLT2 Inhibitors Across the Heart Failure Spectrum
The New Standard of Care: Leveraging the Benefits of SGLT2 Inhibitors Across the Heart Failure Spectrum
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2023

Expires: October 26, 2024

Activities

SGLT2i Across EF
The New Standard of Care: Leveraging the Benefits of SGLT2 Inhibitors Across the Heart Failure Spectrum
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2023

Activities

SGLT2i: Adverse Events
Helping Patients With HF Manage Side Effects of SGLT2 Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2023

Activities

SGLT2i in HF: Medication Adjustments
Considerations for Medication Adjustments in Patients With Heart Failure Initiating or Currently Taking SGLT2 Inhibitors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 13, 2023

Faculty

cover img faculity

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

cover img faculity

Lee R. Goldberg, MD, MPH, FACC, FAHA, FHFSA

Vice Chair of Medicine for Informatics
Section Chief, Advanced Heart Failure and Cardiac Transplant
Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company